SoftOx Solutions AS

SoftOx Solutions AS P/FCF

The P/FCF (Price-to-Free-Cash-Flow Ratio) of SoftOx Solutions AS (SOFTX.OL) as of Oct 23, 2026 is -9.11. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was 13.51 — a change of -167.45% (lower).

P/FCF

-9.11

YoY

-167.45%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of SoftOx Solutions AS is 2025 -9.11 . P/FCF (Price-to-Free-Cash-Flow Ratio) of SoftOx Solutions AS was 2024 13.51 . It decreases by -167.45% lower compared to the previous year.

The SoftOx Solutions AS P/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/FCF
Date
P/FCF
Jan 1, 2018
-10.49 NOK
Jan 1, 2019
-12.49 NOK
Jan 1, 2020
-2.53 NOK
Jan 1, 2021
-2.23 NOK
Jan 1, 2022
-1.89 NOK
Jan 1, 2023
-25.09 NOK
Jan 1, 2024
13.51 NOK
Jan 1, 2025
-9.11 NOK
The SoftOx Solutions AS P/FCF history
YEARP/FCFYoY
-9.11-167.45%
13.51-153.85%
-25.09+1,224.90%
-1.89-15.02%
-2.23-11.79%
-2.53-79.78%
-12.49+19.04%
-10.49+2.71%
-10.22—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SoftOx Solutions AS Stock analysis

What does SoftOx Solutions AS do? SoftOx Solutions AS develops infection control solutions for wounds, disinfection, and respiratory care, with products classified as medical devices or medicinal products. The company's portfolio includes SafeDes+, a hand disinfectant designed for irritated, compromised, and eczematous skin. Its business segments are Wounds, Disinfection, and Respiratory, each focusing on specific medical applications. The firm generates revenue through the sale of its products to healthcare providers and medical institutions within these segments. SoftOx Solutions AS operates through subsidiaries such as SoftOx Disinfection AS, SoftOx Defense Solutions AS, and SoftOx Denmark AS, which support the development and distribution of its product range. The company's products are targeted at healthcare facilities requiring specialized infection control solutions, including hospitals and clinics specializing in wound care, respiratory treatments, and disinfection protocols. Revenue is derived from the commercialization of SafeDes+ and other products within its medical device and medicinal product categories. The company's business model centers on research and product development, with a focus on creating solutions for specific medical needs. Its subsidiaries facilitate the operational structure, enabling the company to manage different aspects of product development and market distribution. Sales are driven by the demand for infection control solutions in healthcare settings, particularly for products addressing skin conditions and respiratory health. SoftOx Solutions AS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SoftOx Solutions AS stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of SoftOx Solutions AS is -9.11 in 2025.

P/FCF (Price-to-Free-Cash-Flow Ratio) of SoftOx Solutions AS changed from 13.51 to -9.11, representing a -167.45% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/FCF (Price-to-Free-Cash-Flow Ratio) SoftOx Solutions AS since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Free-Cash-Flow ratio measures how much investors pay for each unit of free cash flow. A lower ratio may indicate better value.

P/FCF = Market Capitalization / Free Cash Flow

To evaluate P/FCF (Price-to-Free-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/FCF (Price-to-Free-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/FCF (Price-to-Free-Cash-Flow Ratio)'s SoftOx Solutions AS with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — SoftOx Solutions AS

All Key Metrics — SoftOx Solutions AS